NewAmsterdam Pharma Announces 2024 Strategic Priorities
January 04, 2024 08:00 ET
|
NewAmsterdam Pharma N.V
-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to...
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
November 13, 2023 08:00 ET
|
NewAmsterdam Pharma N.V
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 – -- Announced initial data from Phase 2a clinical trial...
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
October 23, 2023 08:00 ET
|
NewAmsterdam Pharma N.V
NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
September 21, 2023 07:00 ET
|
NewAmsterdam Pharma N.V
-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (“CSF”), respectively, indicating potential improvement of cholesterol metabolism in the brain -- --...
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023 08:00 ET
|
NewAmsterdam Pharma N.V
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical...
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
August 14, 2023 16:01 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
August 07, 2023 07:15 ET
|
NewAmsterdam Pharma Company B.V.
-- Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C (p<0.0001) -- --...
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
June 09, 2023 16:01 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, The Netherlands and MIAMI, June 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
June 06, 2023 23:25 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, The Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
June 05, 2023 07:00 ET
|
NewAmsterdam Pharma Company B.V.
-- Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib-- -- 29.7% Median Reduction in Apo B and 37.0%...